# US 2012/0252791 A1 · Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252791 A1
- Document ID: US20120252791A1
- Status: Published application
- Kind: A1
- Application number: 13/496,803
- Filed: 2010-09-16
- Published: 2012-10-04
- Earliest claimed: 2009-09-17
- Inventors: Julian Blagg
- Web page: https://patentgrep.com/patent/US20120252791A1

## CPC

- C07D 473/18: one oxygen and one nitrogen atom, e.g. guanine
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 239/46: Two or more oxygen, sulphur or nitrogen atoms
- C07D 487/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the field of small molecule heterocyclic inhibitors of GTP cyclohydrolase (GCH-I), or a tautomer, prodrug, or pharmaceutically acceptable salt thereof. The invention also features pharmaceutical compositions of the compounds and the medical use of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, or neuropathic pain).

## Claims

### Claim 1

A compound having a structure according to Formula (I):
or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, wherein:
R1, R2, R3, and R4 are each, independently, H, optionally substituted C1-6 alkyl, or R1 and R2, R2 and R3, or R2 and R4 combine to form a double bond,
R5, R6, and R7 are each, independently, H or optionally substituted C1-6 alkyl, and
wherein one and only one of R1 and R2, R2 and R3, or R2 and R4 combine to form a double bond, and
when R5, R6, and R7 are H, R1 and R2 combine to form a double bond and R3 is H, or when R5, R6, and R7 are H, R2 and R3 combine to form a double bond and R1 is H, R4 is not —CH2C6H5, —CH2(p-C6H4—CN), —CH2(p-C6H4—CH3), —CH2CH═CH2, —CH2C(═O)-(p-C6H4-OMe), —CH2C(═O)NH-(o-C6H4-OEt), —CH2C(═O)NH-(2-methoxy-5-chloro-C6H3), —CH2C(═O)NH-(2-methylcyclohexyl), or —CH2C(═O)NH-(p-C6H4—SO2(azepane)).

### Claim 2 (depends on 1)

The compound of claim 1, wherein R5, R6, and R7 are each H.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R6 is optionally substituted C1-6 alkyl.

### Claim 4 (depends on 1, 2)

The compound of claim 1 or 2, wherein R1 and R2 combine to form a double bond.

### Claim 5 (depends on 4)

The compound of claim 4, wherein R3 is H.

### Claim 6 (depends on 1, 2)

The compound of claim 1 or 2, wherein R2 and R3 combine to form a double bond.

### Claim 7 (depends on 6)

The compound of claim 6, wherein R1 is H.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any of claims 1-7, wherein R4 is optionally substituted C1-6 alkyl.

### Claim 9 (depends on 8)

The compound of claim 8, wherein said C1-6 alkyl group comprises a substituent selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, alkenyl, hydroxyl, C1-3 alkoxy, amino, or C1-6 alkylamino, and wherein said aryl or heteroaryl is optionally substituted by C1-4 alkyl, halogen, or nitrile.

### Claim 10 (depends on 1)

The compound of claim 1, wherein said compound has a structure according to one of the following formulas:

### Claim 11 (depends on 10)

The compound of claim 10, or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:

### Claim 12 (depends on 1, 2)

The compound of claim 1 or 2, wherein R2 and R4 combine to form a double bond.

### Claim 13 (depends on 1, 2)

The compound of claim 1 or 2, wherein said compound has a structure according to one of the following formulas:

### Claim 14 (depends on 13)

The compound of claim 13, wherein said compound is selected from the group consisting of:

### Claim 15

A compound having a structure according to Formula (III):
or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, wherein
X1 is O or NR1;
X2 is O or NR2;
R1 and R2 are each, independently, selected from H, or optionally substituted C1-6 alkyl;
R3 is H, halogen, or NR8R9, or R3 combines with R4 to form an oxo group; and
R4 combines with R1 or R2 to form a C═N bond or R4 combines with R3 to form an oxo group;
R5, R6, R7, R8, and R9 are each, independently, H or optionally substituted C1-6 alkyl; and
when R5, R6, and R7 are H, X1 is NR1, R1 and R4 combine to form a C═N double bond, and X2 is NH, R3 is not H or NH2, and
when R5, R6, and R7 are H, X1 is NH, R3 combines with R4 to form an oxo group, and X2 is NR2, R2 is not H.

### Claim 16 (depends on 15)

The compound of claim 15, wherein R5, R6, R7, R8, and R9 are each H.

### Claim 17 (depends on 15, 16)

The compound of claim 15 or 16, wherein said C1-6 alkyl group comprises a substituent selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, C1-3 alkoxy, amino, or C1-6alkylamino, and wherein said aryl or heteroaryl is optionally substituted by C1-4 alkyl, halogen, or nitrile.

### Claim 18 (depends on 15, 16, 17)

The compound of any of claims 15-17, wherein said compound has the following structure:

### Claim 19 (depends on 18)

The compound of claim 18, wherein said compound is selected from the group consisting of:

### Claim 20 (depends on 15, 16, 17)

The compound of any of claims 15-17, wherein X1 is NR1, X2 is NR2, R1 and R2 are each, independently, H or optionally substituted C1-6 alkyl, and R3 combines with R4 to form an oxo group.

### Claim 21 (depends on 20)

The compound of claim 20, wherein said compound is

### Claim 22 (depends on 15, 16, 17)

The compound of any of claims 15-17, wherein said compound has a structure according to

### Claim 23 (depends on 22)

The compound of claim 22, wherein R3 is H.

### Claim 24 (depends on 22, 23)

The compound of claim 22 or 23, wherein said compound has a structure according to
and wherein R2 is optionally substituted C1-6 alkyl.

### Claim 25 (depends on 24)

The compound of claim 24, wherein said C1-6 alkyl group comprises a substituent selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, C1-3 alkoxy, amino, or C1-6alkylamino, and wherein said aryl or heteroaryl is optionally substituted by C1-4 alkyl, halogen, or nitrile.

### Claim 26 (depends on 24)

The compound of claim 24, wherein R3 is Cl or Br.

### Claim 27 (depends on 22)

The compound of claim 22, wherein said compound is selected from the group consisting of:

### Claim 28 (depends on 15, 16, 17)

The compound of any of claims 15-17, wherein said compound has a structure according to the following formula:

### Claim 29 (depends on 28)

The compound of claim 28, wherein R5, R6, R7, R8, and R9 are each H, and R2 is optionally substituted C1-6 alkyl.

### Claim 30 (depends on 28)

The compound of claim 28, wherein R2 is H.

### Claim 31 (depends on 28, 29, 30)

The compound of any of claims 28-30, wherein said C1-6 alkyl group comprises a substituent selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, C1-3 alkoxy, amino, or C1-6alkylamino, and wherein said aryl or heteroaryl is optionally substituted by C1-4 alkyl, halogen, or nitrile.

### Claim 32 (depends on 29)

The compound of claim 29, wherein said compound is

### Claim 33

A compound having a structure according to
or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, or according to
or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6, and R7 are each, independently, H or optionally substituted C1-6 alkyl.

### Claim 34 (depends on 33)

The compound of claim 33, wherein R5, R6, and R7 are each H.

### Claim 35 (depends on 33, 34)

The compound of claim 33 or 34, wherein R1 and R3 are both H.

### Claim 36 (depends on 33, 34, 35)

The compound of any of claims 33-35, wherein said C1-6 alkyl group comprises a substituent selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, C1-3 alkoxy, amino, or C1-6alkylamino, and wherein said aryl or heteroaryl is optionally substituted by C1-4 alkyl, halogen, or nitrile.

### Claim 37 (depends on 36)

The compound of claim 36, wherein R2 is H.

### Claim 38 (depends on 37)

The compound of claim 37, wherein said compound is selected from the group consisting of:

### Claim 39

A compound selected from the group consisting of:
or a tautomer, prodrug, or pharmaceutically acceptable salt thereof,
and
or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, wherein each of R1, R6, and R7, is H or optionally substituted C1-6 alkyl.

### Claim 40 (depends on 39)

The compound of claim 39, wherein R6 and R7 are both H.

### Claim 41 (depends on 39)

The compound of claim 39, wherein said C1-6 alkyl group comprises a substituent selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, C1-3 alkoxy, amino, or C1-6alkylamino, and wherein said aryl or heteroaryl is optionally substituted by C1-4 alkyl, halogen, or nitrile.

### Claim 42 (depends on 41)

The compound of claim 41, wherein R1 is H.

### Claim 43 (depends on 39)

The compound of claim 39, wherein said compound is
or a tautomer, prodrug, or pharmaceutically acceptable salt thereof.

### Claim 44

A compound according to Formula (VI),
or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, wherein each of R1, R2, R6, and R7 is, independently, H or optionally substituted C1-6 alkyl.

### Claim 45 (depends on 44)

The compound of claim 44, wherein R6 and R7 are both H.

### Claim 46 (depends on 44)

The compound of claim 44, wherein said compound is

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The compound of any of claims 1-46, wherein said compound is an inhibitor of GTP cyclohydrolase (GCH-1).

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A pharmaceutical composition comprising the compound of any of claims 1-47, or any of the following compounds,
or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A method of treating, reducing, or preventing a condition in a mammal, wherein said method comprises the administration of the compound of any of claims 1-47, or any of the following compounds,
or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 48, to said mammal in a dosage sufficient to inhibit GCH-1.

### Claim 50 (depends on 49)

The method of claim 49, wherein said condition is pain.

### Claim 51 (depends on 50)

The method of claim 50, wherein said pain is neuropathic, inflammatory, nociceptive, or functional pain.

### Claim 52 (depends on 50, 51)

The method of claim 50 or 51, wherein said pain is chronic pain.

### Claim 53 (depends on 50, 51)

The method of claim 50 or 51, wherein said pain is acute pain.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A method of inhibiting GCH-1 in a cell, wherein said method comprises contacting a cell with any of the compounds of claims 1-47, or any of the following compounds,
or a tautomer, prodrug, or pharmaceutically acceptable salt thereof.
